300702SZSE

Announcement on the Company's API Passing CDE Review

Zhejiang Tianyu Pharmaceutical Co., Ltd.··2 pages

✨ AI Summary

Zhejiang Tianyu Pharmaceutical Co., Ltd. announces that its CDE review for the API "Brivaracetam" has been accepted. The API is used for adjunctive treatment of partial-onset seizures. The company expects to obtain GMP compliance inspection results and then apply for domestic market sales. The listing time is uncertain due to market factors.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300702 Stock Abbreviation: Tianyu Shares Announcement No.: 2026-047

Zhejiang Tianyu Pharmaceutical Co., Ltd. Announcement on the Company's API Passing CDE Review

The Board of Directors and all directors of the Company guarantee that the information disclosed in this announcement is free from false representations, misleading statements, or material omissions, and that they shall bear individual and joint legal responsibility for the truthfulness, accuracy, and completeness of this information.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Sign in to read moreSee Pro pricing